ABSTRACT
Objetive: To compare in vitro bacterial adherence on teeth submitted to whitening with 50% ethanolic extract of Musa paradisiaca and 35% hydrogen peroxide. Material and Methods: The study was experimental and used 18 premolars that were grouped into: G1 (control), G2 (50% ethanol extract of Musa paradisiaca) and G3 (35% hydrogen peroxide). The teeth were then exposed to a Streptococcus mutans culture for 24 hours, followed by centrifugation in thioglycolate broth. A culture on trypticase soy agar was done with a 1 in 100 dilution, and after 48 hours colony forming units (CFU) were counted. Statistical analysis was performed using the ANOVA test, complemented by the Bonferroni post-hoc. Results: Bacterial adherence was 77x105 CFU/ml in Group 3 using 35% hydrogen peroxide, 40x105 CFU/ml in Group 2 using 50% ethanol extract of Musa paradisiaca, and 89x104 CFU/ml in Group 1 (control). The difference between the three groups was significant (p=0.000). Conclusion: Both whitening methods cause bacterial adherence to the tooth surface, although to a lower degree with Musa paradisiaca.eses.
Objetivo: Comparar la adherencia bacteriana in vitro en dientes sometidos a blanqueamiento con extracto etanólico de Musa paradisiaca al 50% y con peróxido de hidrógeno al 35%. Material y Métodos: Comparar la adherencia bacteriana in vitro en dientes sometidos a blanqueamiento con extracto etanólico de Musa paradisiaca al 50% y con peróxido de hidrógeno al 35%.Resultados: La adherencia bacteriana fue de 77x105 UFC/ml con el peróxido de hidrógeno al 35%, de 40x105 UFC/ml con el extracto etanólico de Musa paradisiaca al 50% y de 89x104 UFC/ml con el control. La diferencia fue significativa entre los tres grupos (p=0.000). Conclusión: Ambos métodos de blanqueamiento causan adherencia bacteriana en la superficie dental, siendo menor con Musa paradisiaca.
Subject(s)
Humans , Tooth Bleaching/methods , Bacterial Adhesion/drug effects , Musa/microbiology , Hydrogen Peroxide/therapeutic use , Peru , Streptococcus mutans/drug effects , Bicuspid , In Vitro TechniquesABSTRACT
COVID-19, a disease caused by the novel coronavirus SARS-CoV-2, has produced a serious emergency for global public health, placing enormous stress on national health systems in many countries. Several studies suggest that cytokine storms (interleukins) may play an important role in severe cases of COVID-19. Neutralizing key inflammatory factors in cytokine release syndrome (CRS) could therefore be of great value in reducing the mortality rate. Tocilizumab (TCZ) in its intravenous (IV) form of administration-RoActemra? 20 mg/mL (Roche)-is indicated for treatment of severe CRS patients. Preliminary in-vestigations have concluded that inhibition of IL-6 with TCZ appears to be efficacious and safe, with several ongoing clinical trials. This has led to a huge increase in demand for IV TCZ for treating severe COVID-19 patients in hospitals, which has resulted in drug shortages. Here, we present a comparability study assessing the main critical physicochemical attributes of TCZ solutions used for infusion, at 6 mg/mL and 4 mg/mL, prepared from RoActemra? 20 mg/mL (IV form) and from RoActemra? 162 mg (0.9 mL solution pre-filled syringe, subcutaneous(SC) form), to evaluate the use of the latter for preparing clinical solutions required for IV administration, so that in a situation of shortage of the IV medicine, the SC form could be used to prepare the solutions for IV delivery of TCZ. It is important to remember that during the current pandemic all the medicines are used off-label, since none of them has yet been approved for the treatment of COVID-19.
ABSTRACT
Cetuximab (CTX) is a potent chimeric mouse/human monoclonal antibody (mAb) approved worldwide for treatment of metastatic colorectal cancer. Among the various biological and physical analyses per-formed for full study on this biopharmaceutic, the determination of the concentration preparations throughout manufacturing and subsequent handling in hospital is particularly relevant. In the present work, the study and validation of a method for quantifying intact CTX by reverse-phase high-perfor-mance liquid chromatography with diode array detection ((RP)HPLC/DAD) is presented. With that end, we checked the performance of a chromatographic method for quantifying CTX and conducted a study to validate the method as stability-indicating in accordance with the International Conference on Harmo-nization guidelines (ICH) for biotechnological drugs; therefore, we evaluated linearity, accuracy, preci-sion, detection and quantification limits, robustness and system suitability. The specificity of the method and the robustness of the mAb formulation against external stress factors were estimated by compre-hensive chromatographic analysis by subjecting CTX to several informative stress conditions. As de-monstrated, the method is rapid, accurate, and reproducible for CTX quantification. It was also suc-cessfully used to quantify CTX in a long-term stability study performed under hospital conditions.